The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
FDA’s Oncologic Drugs Advisory Committee (ODAC) critiques a major lymphoma trial for having too few U.S. participants, warning …
Novavax’s protein-based COVID-19 vaccine, Nuvaxovid, wins FDA approval for older adults and people with underlying health risks under …
A new antibody-drug conjugate brings hope for patients with lung cancer who have few options
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
First new targeted therapy in more than a decade offers relief to patients with hives uncontrolled by antihistamines
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
Already a subscriber? Log in